Tacrolimus Powder CAS 104987-11-3 Fujimycin
Cabozantinib Pharmaceutical CAS 849217-68-1
Ceritinib Powder Anti-Cancer CAS 1032900-25-6
Ponatinib Powder CAS 943319-70-8 Intermediate
Ibrutinib Powder CAS 936563-96-1 Anti-Cancer
Dasatinib Monohydrate CAS 863127-77-9 API
Afatinib Raw Material CAS 850140-72-6
Dasatinib Monohydrate Anticancer 863127-77-9
The global anticancer drug industry is currently navigating a period of unprecedented transformation. As cancer remains one of the leading causes of mortality worldwide, the demand for sophisticated therapeutic solutions has surged. According to recent market analysis, the global oncology drugs market is projected to reach over $300 billion by 2027, growing at a CAGR of approximately 11.5%. This growth is driven by a shift from traditional chemotherapy to precision medicine—specifically targeted therapies and immunotherapies.
Industrial status reveals a heavy reliance on high-quality Active Pharmaceutical Ingredients (APIs) and chemical intermediates. Manufacturers are now focusing on small molecule inhibitors like Ibrutinib and Dasatinib, which offer higher selectivity and fewer side effects compared to cytotoxic agents. The supply chain has become increasingly globalized, with China and India emerging as the primary hubs for raw material synthesis and API manufacturing, supplying over 60% of the world's pharmaceutical precursors.
The industry is moving away from a "one-size-fits-all" approach. Drugs like Afatinib and Ceritinib are designed to target specific genetic mutations in cancer cells, such as EGFR or ALK, minimizing damage to healthy tissues.
Artificial Intelligence is now used to predict how anticancer compounds interact with biological targets, significantly reducing the R&D timeline for new molecules and optimizing manufacturing processes.
Combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs, ADCs represent the next frontier in oncology, requiring extremely high-purity chemical intermediates.
Modern manufacturers are adopting sustainable chemical synthesis routes to reduce hazardous waste, aligning with global ESG (Environmental, Social, and Governance) standards for pharmaceutical production.
Global procurement teams from pharmaceutical giants, research hospitals, and generic drug manufacturers are constantly seeking reliable Anticancer Drugs Manufacturers & Exporters. The primary concern is no longer just price, but a combination of regulatory compliance (GMP/ISO), purity consistency, and supply chain resilience.
Ibrutinib is a potent, selective, and irreversible small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It is widely utilized in the treatment of various B-cell malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. Our factory provides 99%+ purity Ibrutinib powder, ensuring the highest standards for pharmaceutical formulation.
As a core product in our oncology portfolio, we offer full documentation support and stable lead times for international exporters.
China has solidified its position as the "Pharmacy of the World" due to its robust chemical infrastructure and skilled workforce. At Hangzhou Jeci Biochem Technology Co., Ltd., we represent the pinnacle of Chinese pharmaceutical expertise. Our location in Hangzhou—a hub of biotechnology—allows us to integrate R&D with efficient mass production.
We leverage integrated supply chains to offer competitive pricing without compromising on material quality.
Our collaborative R&D team works with top institutes to provide custom synthesis for complex molecules.
Experienced in international trade with India, SE Asia, and Japan, ensuring seamless customs clearance.
Paclitaxel remains a cornerstone of cancer chemotherapy, used to treat lung, ovarian, breast, and head and neck cancers. It works by interfering with the normal breakdown of microtubules during cell division. Our Paclitaxel is sourced and refined under strict quality control measures to ensure therapeutic efficacy.
We provide comprehensive CoA (Certificate of Analysis) and HPLC data for every batch to meet the stringent requirements of global pharmaceutical buyers.
Hangzhou Jeci Biochem Technology Co., Ltd. is located in Hangzhou, Zhejiang Province. We are committed to sales of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, nutritional products and food additives, cooperative R & D, custom manufacturing, sales and service as well as import of these kinds of materials.
In China, we have a strong collaborative R&D team, working in depth with new drug research institutes and multiple custom processing plants. We have very good domestic sales channels and have long-term relationships with domestic companies, including product applications, technology transfer, product supply, custom processing, and exclusive agents for multiple products in multiple regions. In addition, we also provide factory quality management system certification consulting services.
Our drugs and intermediates are essential substances for the production of advanced therapeutics and are widely used in:
We are able to assemble and produce larger quantities of intermediates and provide some advanced, convenient manufacturing capabilities, including batch processing and customization. For the company's main product intermediates: We can maximize our advantages, meet the requirements of most customers and complete the task within the specified time limit.
Paclitaxel Anticancer Dietary Supplement Material
Gemcitabine Hydrochloride Antineoplastic
Trametinib API CAS 871700-17-3 Raw Material
Crizotinib Anticancer CAS 877399-52-5
Axitinib Powder CAS 319460-85-0 Drug
Daclatasvir Powder CAS 1009119-64-5
Cabozantinib Powder CAS 849217-48-7
Velpatasvir Powder Anticancer API Material
SJ medical